跳至主要内容

New non-small cell lung cancer study to explore genetics of mutation

There were an estimated 410,000 new cases of lung cancer and 353,000 deaths from lung cancer in Europe in 2012. This makes lung cancer the fourth most common cancer site (after female breast, 464,000 cases, colorectal, 447,000 cases, and prostate, 417,000 cases) but the leading cause of cancer death in Europe. It is a frequent and deadly disease.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for 85% of all lung cancer cases, and although numerous studies have documented a higher risk for developing NSCLC among smokers, non-smokers also develop lung cancer. This suggests that there are additional risk factors involved in developing this disease. It is thought that both somatic gene mutations (mutations that can occur in the cancer), as well as germline gene mutations (mutations that are inherited), contribute to NSCLC carcinogenesis.
Somatic epidermal growth factor receptor (EGFR) mutations occur more frequently in females and in East Asian patients. Therefore, the EORTC 08114-GEM intergroup translational research-observational study is designed to explore the underlying genetic factors associated with development of EGFR mutant NSCLC. The study seeks to catalogue the distribution of somatic EGFR mutant genotypes in 1,000 EGFR mutant NSCLC cases and describe their relationship to clinical outcome, identify germline DNA variants associated with somatic EGFR mutations in NSCLC, to correlate their relationship with survival, and finally to investigate germline DNA variants associated with development of NSCLC in this cohort of predominantly never/ex-light smokers.
Dr. Sanjay Popat of the Royal Marsden Hospital - Chelsea, London, and Coordinator of this trial says, “We are developing a good understanding of the molecular events that drive lung cancer. The best characterized of these is somatic EGFR mutation. Still, the genetic reasons why EGFR mutations occur in lung cancer, predominantly in never smokers, females, adenocarcinomas, and in East Asian patients are not well understood. So, this study will enroll patients with somatic EGFR mutant lung cancer, and a best "environmentally matched" control population of patients without the EGFR mutation, aiming to identify DNA variants associated with development of the EGFR mutation, and to assess their possible influence on patient survival.”
The EORTC intergroup 08114-GEM trial plans to accrue a total of 2000 patients. The Case Group will comprise 1,000 patients with EGFR mutant NSCLC, and the Control Group will comprise 1,000 patients with EGFR wild type NSCLC who either never smoked or are ex-light smokers. It will be conducted in more than 50 sites in several countries including Belgium, Egypt, Greece, Poland and the United Kingdom (UK). This trial is led by the EORTC Lung Cancer Group in collaboration with the UK National Cancer Research Institute and Professor Mark Lathrop at the Genome innovation Centre, Quebec, Canada. This is an academic trial supported by the EORTC Lung Cancer Group without any support from industry.
Find out more "www.medicilon.com"

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文